Peijia Medical
An interventional medical products provider.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $128m | Private Placement VC | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 253 % | 84 % | 76 % | 40 % | 30 % | 24 % | 36 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (401 %) | (143 %) | (74 %) | (22 %) | (7 %) | 7 % | 19 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (421 %) | (163 %) | (89 %) | (37 %) | (11 %) | (1 %) | 9 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 327 % | 149 % | 67 % | 33 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Peijia Medical Limited, established in 2012 and headquartered in Suzhou, China, is a prominent player in the interventional procedural medical device market. The company focuses on developing and providing innovative medical devices aimed at treating structural heart diseases and neurovascular diseases. Peijia Medical serves healthcare providers and hospitals, primarily within the Chinese market, but aims to expand its reach globally. The business model revolves around the research, development, and commercialization of advanced medical devices, generating revenue through the sale of these products. The company is listed on the Main Board of the Hong Kong Stock Exchange, reflecting its growth and investor confidence.
Keywords: interventional, medical devices, structural heart, neurovascular, innovation, healthcare, China, hospitals, commercialization, Hong Kong Stock Exchange.
Tech stack
Investments by Peijia Medical
Edit